Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지

Single and Four-Week Repeated Oral Toxicity Study of CJ-11555 in Sprague-Dawely Rats

CJ-11555의 Sprague-Dawely 랫드를 이용한 단회 및 4주 반복경구투여 독성시험

  • Published : 2004.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

This study was to investigate single and repeated-dose toxicities of CJ-11555, an anticirrhotic agent, in Sprague-Dawley (SO) rats. In single-dose oral toxicity study, the test article were administered once by gavage to males and females at dose levels of 0 and 2,000 mg/kg. No dead animals and abnormal necropsy findings were found in control and CJ-11555 treated group. Therefore, the approximate lethal dose of CJ-11555 was considered to be higher than 2,000 mg/kg in rats. In the 4-week repeated oral toxicity study, the test article was administered once daily by gavage to male and female rats at dose levels of 0, 10, 50 and 200 mg/kg/day for 4-weeks. In clinical signs, yellow-colored urine and yellow hair coat were observed in the 50 and 200 mg/kg male and female groups. In hematology, erythrocyte count and hemoglobin were significantly decreased in the 200mg/kg male and female groups. In serum biochemistry, total cholesterol was significantly increased and aspartate aminotransferase (AST) was significantly decreased in the 50 or 200 mg/kg male and female groups. In histopathological examinations, centrilobular hepatocellular hypertrophy in the liver, congestion and pigmentation in the spleen, hyaline droplets in the kidney were observed in the 50 and 200 mg/kg male and female groups. In toxicokinetic study, CJ-11555 was dose-dependent in systemic exposure and showed better absorption in female with minimum accumulation after multidosing. Based on these results, it was concluded that the 4-week repeated oral dose of CJ-11555 resulted in the suppression of AST activity and centrilobular hepatocellular hypertrophy in both sexes at a dose level of 50 or 200 mg/kg/day. The target organ was estimated to be liver, spleen and male's kidney. The no-observed-adverse-effect level (NOAEL) for CJ-11555 in rats following gavage for at least 4-week is 10 mg/kg/day.

Keywords

References

  1. 양기화 (2000): 독성병리진단기준해설(랫드편), 국립독성연구소. 의약품등의 독성시험기준. 식품의약품안전청 고시 제 1999-61호, 식품의약품안전청, 서울
  2. Ansher, S. (1985): The chemotherapy of schistosomiasis. Ann. Rev. Pharmacol., 25, 485-508
  3. Buetler, T.M., Galiaagher, E.P., Wang, C., Stahl, D.L., Hayes, J.D. and Eaton, D.L.(1995): Induction of phase I and II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and Oltipraz. Toxicol. Appl. Pharmacol., 135, 45-57
  4. Crowell, J.A., Page, J.G., Rodman, L.E., Heath, J.E., Goldenthal, E.I., Hall, L.B. and Kellott, G.J. (1997): Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione, a potential chemopreventive agent. Fund Appl. Taxical., 35, 9-21
  5. Heusse, D., Marlard, m., Bredenbac, J., Decdouvelaere, B., Leroy, J.P., Bieder, A. and Jumeau, H. (1985). Disposition of 14C-Oltipraz in animals. Pharmacokinetics in mice, rats, and monkeys. Comparison of the biotransformation in the infected mouse and in the schistosomes. Arzneimittelforschung. 35, 1431-1436
  6. Gopinath, C., Prentice, D.E. and Lewis, D.J. (1987): Atlas of experimental toxicological pathology, MTP Press, pp. 135
  7. Greaves, P. (2000): Histopathology of preclinical toxicity studies: Interpretation and relevance in drug evaluation, Second Edition, Elsevier, pp. 114, 227, 576, 638, 760, 850
  8. Kang, K.W., Choi, S.H., Ha, J.R., Kim. C.W. and Kim, S.G. (2002a): Inhibition of dimethylnitrosamine-induced liver fibrosis by [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] (oltipraz) in rats: suppression of transforming growth factor-beta1 and tumor necrosis factor-alpha expression. Chem. Biol. Interact., 139, 61-67.
  9. Kang, K.W., Kim, Y.G., Cho, M.K., Bae, S.K., Kim, C.W., Lee, M.G. and Kim, S.G. (2002b): Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding proteinmediated stellate cell inactivation. FASEB J., 16, 1988-1990
  10. Kensler, T.W., Egner, .PA., Wang, J.B., Zhu, Y.R., Zhang, B.C., Oian, G.S., Kuang, S.Y., Gange, S.J., Jacobson, L.P., Munoz, A. and Groopman, J.D. (2002a): Strategies for chemoprevention of liver cancer. Eur. J. Cancer Prev., 2, 58-64
  11. Kensler, T.W., Egner, P.A., Dolan, P.M., Groopman, J.D. and Roebuck, B.D. (1987b). Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl1,2-dithiol-3-thione (Oltipraz) and related 1,2-dithio-3thiones and 1,2-dithiol-3-thione. Cancer Res., 47, 4271-4277
  12. Turton, J. and Hooson, J. (1998): Target organ Pathology, A basic text, Taylor & Francis, pp. 81
  13. Walter, F.L. and Fred, W,Q. (1989): The clinical chemistry of laboratory animals, Pergamon Press, pp. 179-182, 260